Aurobindo gets USFDA nod for Lamivudine

Aurobindo Pharma has received a tentative US Food and Drug Administration (USFDA) approval for Lamivudine oral solution (10 mg/ml).

According to a release issued by Aurobindo Pharma to the BSE today, Lamivudine is prescribed to treat infections due to Hepatitis-B and HIV in combination with other HIV drugs.